Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There was a spike in volume friday and RXAF dropped, thus I bought. WoW! There really is no one on this board? I think this is bouncing anyways. Happy New Year to anyone that sees this!!
A:Because he's one of the obsequious toadies, sycophant sock-puppets, and paid pumping pimp-shills that's been hired for this year's P&D.
What makes you say that?
Probably nothing more than the Annual Pump-And-Dump, but who knows.
RXAF has been on fire lately. Anyone know what is up?
Heads up! Showing signs of life on the chart:
http://stockcharts.com/h-sc/ui?s=RXAF&p=D&yr=0&mn=6&dy=0&id=p47685589114&a=194180354
rest of this week's trading should tell the tale if something real is in the works, or this is just a head-fake.
It is a "Margie Chassman" Company bro.
BUY everything that she is in. everything. These "people" are professioanl Grifters. They are the people that Washtrade stocks to high levels. these are the SCUM of the WALLSTREET. the Original Pump and Dump Penny promoters.
ya what do you think about this mess of a pinkie?
the stock is primed for a pump. ole Margie knows.
Phone Conference Call Now Available!! Looks Good...
http://rxforafrica.com/conf_calls/2009_0611%20RXAF%20Conference%20Call.wav
-OR-
http://rxforafrica.com/conference_calls.htm
Just this morning, RXAF announced huge news of a signing of a letter of intent for a strategic alliance with Rusan Pharma, Ltd., of Mumbai , India .
http://www.wallstreetgrand.com/profiles55.html
Getting featured..
http://www.wallstreetgrand.com/profiles.html
Sitting long here myself this is going to worth the patience
fwiw..Current Promotion
Lebed Biz LLC has been compensated by RXAF $15,000 cash for a one-month investor relations contract
Classic Lebed lead pump....
New pump comes out @ the open and the stock drops 20%+/- on HUGE volume....
chartman, first on the scene as usual..eom
RXAF Chart looking good again. Nice rolling chart. MACD wants to turn postive.
I love the chart and recent surge in the pps. Holding tight to my shares.
NEWS
Diamond Entertainment Corporation Announces the Sale of its DVD Business
Thursday July 26, 6:30 am ET
LOS ANGELES--(BUSINESS WIRE)--Diamond Entertainment Corporation (OTCBB:DMON - News), in accordance with its change in business direction pursuant to its merger with RX for Africa, Inc., announced today that it has sold its inventory of Electronic Media and certain other related assets.
"We are in position to focus all our attention to searching for innovative solutions to the critical challenge of meeting the healthcare needs of those living in Africa," commented Dr. Mulugetta Bezzabeh, the new CEO of Diamond Entertainment Corporation and continuing CEO of Rx Africa (Ethiopia) PLC.
About Rx for Africa, Inc.
Rx for Africa, Inc. is a holding company headquartered in New York City which was recently acquired by a newly formed subsidiary of Diamond Entertainment Corporation, a publicly traded company (DMON). At present, the primary asset of Rx for Africa, Inc. is its 100% ownership interest in Rx Africa (Ethiopia) PLC, a pharmaceutical company based in Addis Ababa, Ethiopia.
About Rx Africa (Ethiopia) PLC
Rx Africa (Ethiopia) PLC is a pharmaceutical company, formerly known as Sunshine Pharmaceutical, which owns and operates a pharmaceutical manufacturing facility in Addis Ababa, Ethiopia. The plant was established to manufacture AIDS/HIV, malaria, tuberculosis and other generic drugs in Ethiopia. Rx Africa (Ethiopia) PLC is currently producing six generic products for distribution in Ethiopia, with plans to increase its product line by a minimum of 30 new generic medicines over the next six months for sale throughout Ethiopia and the rest of Africa.
Unusual high volume today without price movement. Could news be on the way? I'm still hanging in there.
Russia warns of AIDS epidemic, 1.3 mln with HIV
By Guy Faulconbridge
Tue May 15, 12:23 PM ET
MOSCOW (Reuters) - Russia's AIDS epidemic is worsening with as many as 1.3 million people infected with HIV as the virus spreads further into the heterosexual population, Russia's top AIDS specialist said on Tuesday.
Russia has registered 402,000 people with HIV, of whom 17,000 have died, but the real figure is much higher, said Vadim Pokrovsky, head of Russia's federal AIDS centre.
"Not only is the number of Russians infected with HIV rising but there is an increase in the rate at which the epidemic is spreading, so a rise in the number of newly infected," Pokrovsky told reporters.
"We have an estimate of up to 1.2 million to 1.3 million infected with HIV," he said, adding that the number of those registered as infected was rising by 8 to 10 percent a year.
The United Nations estimates 65 million people worldwide have been infected with HIV and that 25 million people have been killed by AIDS since it was first recognized in 1981.
AIDS, which stands for Acquired Immune Deficiency Syndrome, is caused by the human immunodeficiency virus (HIV).
Most of those infected with HIV are unaware they are carrying the virus, according to the UN.
"ONE IN TEN MALES"
Pokrovsky said HIV was high among Russia's intravenous drug users but that many of those newly infected were not needle users. And he warned that the virus was spreading fast into the heterosexual population.
Women made up 44 percent of 39,589 registered new infections last year, he said adding that in some cities one in ten Russian males were infected with HIV.
"Evidence of the strengthening heterosexual HIV infection is the increase in the number of women among those newly registered with HIV," Pokrovsky said.
"On average for the country, one out of every fifty males is infected with HIV but in some cities it is one in ten," he said.
Russia's northern city of St Petersburg was worst affected followed by Sverdlovsk region, greater Moscow, Samara region and Moscow, though Pokrovsky said figures for Moscow were probably much higher than the data indicated.
The United Nations said in a report published on Tuesday that HIV was higher in richer regions.
"HIV prevalence is in an inverse relationship to economic development: HIV is more widespread in 'rich' regions," the UN said in a report about Russia's regions.
Pokrovsky said overall funding for fighting AIDS in Russia was rising but that just 200 million roubles ($7.75 million) would be spent on prevention in 2007 out of a total budget of 5.3 billion roubles ($205.4 million).
"The financing is sharply rising," he said. "There is now a lot of money, but the spending is not done entirely properly."
"A very small amount of that money...is directed to preventing the further spread of the epidemic; most of it is being used for treatment. That is good but you need prevention too," he said.
Chart has pretty much bottomed. I am hoping one of the 30 new drugs is to fight the bird flu. If it is then we fly. no pun intended. lol
still in!!!!!!!buying more on dips.....slow and steady...still thinking this goes to $1.00 or so very soon....price now is below the private placement...can't stay her too long....only my opinion
StrategicAdvisor007 are you still in?
Very Depressing. PPS cut in half in less than a month. Down ticks on low volume. Maybe setting up for a double bottom? Anyway this is a longterm investment for me.
News.........................
Announces Merger with Rx Africa (Ethiopia) PLC and Diamond Entertainment Corporation
Friday May 4, 6:30 am ET
NEW YORK--(BUSINESS WIRE)--Rx for Africa, Inc. announced today it has merged with Rx Africa (Ethiopia) PLC, formerly known as Sunshine Pharmaceutical, and Diamond Entertainment Corporation, a publicly held corporation (OTCBB:DMON - News) headquartered in Walnut, California. Rx Africa (Ethiopia) PLC owns and operates a state-of-the-art pharmaceutical plant built on twenty three thousand square meters of land located south of Addis Ababa, Ethiopia. The facility was established to manufacture HIV/AIDS, malaria, tuberculosis and other generic drugs for distribution initially in Ethiopia and eventually throughout Africa. The company is currently producing and marketing a total of six products, and is in the process of scaling up its production with the expectation of producing at least 30 new products by late 2007.
"We are proud to join the ranks of publicly traded pharmaceutical companies searching for innovative solutions to the critical challenge of meeting the healthcare needs of those living in Africa," commented Dr. Mulugetta Bezzabeh, new CEO of Diamond Entertainment Corporation and continuing CEO of Rx Africa (Ethiopia) PLC. "We intend to be a major factor in the manufacturing and distribution of much-needed medicines not only in Ethiopia, but also throughout Africa. We believe that Ethiopia and many other African countries are poised for very rapid growth of the private sector over the next five years, and Rx for Africa, Inc. intends to be a participant in that growth."
Dr. Bezzabeh continued, "We are in the process of reworking our facilities to bring them into US Food and Drug Administration and World Health Organization GMP (Good Manufacturing Practices) compliance. We expect to have this work completed within calendar 2007. These upgrades will make Rx Africa (Ethiopia) PLC eligible to receive some of the billions of dollars available from programs such as the President's Emergency Program for AIDS Relief (PEPFAR) and various World Health Organization initiatives.
"We are excited and proud to have reached this important milestone, which will bring us credibility and visibility in the U.S. and also allow us to access the public capital markets."
About Rx for Africa, Inc.
Rx for Africa, Inc. is a holding company headquartered in New York City which was recently acquired by a newly formed subsidiary of Diamond Entertainment Corporation, a publicly traded company (DMON). At present, the primary asset of Rx for Africa, Inc. is its 100% ownership interest in Rx Africa (Ethiopia) PLC, a pharmaceutical company based in Addis Ababa, Ethiopia.
About Rx Africa (Ethiopia) PLC
Rx Africa (Ethiopia) PLC is a pharmaceutical company, formerly known as Sunshine Pharmaceutical, which owns and operates a pharmaceutical manufacturing facility in Addis Ababa, Ethiopia. The plant was established to manufacture AIDS/HIV, malaria, tuberculosis and other generic drugs in Ethiopia. Rx Africa (Ethiopia) PLC is currently producing six generic products for distribution in Ethiopia, with plans to increase its product line by a minimum of 30 new generic medicines over the next six months for sale throughout Ethiopia and the rest of Africa.
About Diamond Entertainment Corporation
Diamond Entertainment Corporation is a publicly traded company (DMON) incorporated in New Jersey and headquartered in Walnut, California. Through a newly formed, special purpose subsidiary, Diamond Entertainment Corporation recently completed the acquisition of Rx for Africa, Inc., a holding company based in New York City which is the parent company of Rx Africa (Ethiopia) PLC, a pharmaceutical company based in Addis Ababa, Ethiopia. Prior to its acquisition of Rx for Africa, Inc., Diamond Entertainment was principally in the business of distributing and selling videocassette/DVD programs through normal distribution channels throughout the United States.
should start moving up............
Great to see I am no alone in this stock. Trading has been tight over the last few weeks. Also notice a higher new base. A small step up from the base a few weeks ago. Volume has been light.
I am in...........
StrategicAdvisor007, Are you in buddy? I can't wait until the market finds this little gem.
Some bid wicking going on but its fine by me since this is a longterm investment for me.
HIV epidemic 'is getting worse'
http://news.bbc.co.uk/1/hi/health/6166530.stm
Aids and Africa Link
http://www.aidsandafrica.com/
Could be any day now.
DMON just had a r/s a few days ago.
DMEC: Immediately prior to the acquisition, DMEC will have 800,000,000 issued and authorized shares outstanding. Subsequent to a 30 to 1 reverse split, 26,666,667 shares will be issued and outstanding.
http://www.secinfo.com/dV3p8.v2v6.6.htm
this is going to be a great stock to own...down the road...RX for Africa
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
122
|
Created
|
03/29/07
|
Type
|
Free
|
Moderators |
| 471,400 | |||
Common stock, no par value; 800,000,000 shares authorized; 20,696,642 issued and outstanding |
Rx for Africa, Inc. Now Trading Under New Symbol (RXAF.PK)
Wednesday October 31, 8:30 am ET
RXAF.PK last 0.0036 0.00 volume: 60,000 1/28/2011 10:47am | |
Management | Rx for Africa, Inc.Investing in Generic Pharmaceutical Manufacturing in Sub-Saharan AfricaANNOUNCEMENT: Replay of conference calls available here. |
Rx for Africa, Inc., a public New Jersey corporation formed in 2007, invests in companies manufacturing generic pharmaceuticals in Sub-Saharan Africa. Rx Africa (Ethiopia) P.L.C. is a wholly-owned operating subsidiary, with a campus just outside Addis Ababa, Ethiopia: factory, R&D center and office facilities, currently producing pharmaceutical products. The company sells 100% of its current production through distributors.
Cimetidine 500mg (film-coated tablet) | A histamine H2-receptor antagonist that inhibits the production of acid in the stomach. It is largely used in the treatment of heartburn and peptic ulcers. | |
Ciprofloxacin 500mg (film-coated tablet) | Ciprofloxacin is bactericidal. Its mode of action depends upon blocking bacterial DNA replication by binding itself to an enzyme called DNA gyrase, thereby inhibiting the unwinding of bacterial chromosomal DNA during and after the replication. | |
Doxycycline 500mg (capsule) | A member of the tetracycline antibiotics group, it is commonly used to treat a variety of infections. Doxycycline is frequently used to treat chronic prostatitis, sinusitis, syphilis, chlamydia, pelvic inflammatory disease and acne. In addition it is used in the treatment and prophylaxis of anthrax and in prophylaxis against malaria | |
Norfloxacin 500mg (film coated tablet) | An oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections. It is also sometimes used to treat stomach infections. | |
Omeprazole 500mg (pellet) | A proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. | |
Tinidazole 500mg (film-coated tablet) | An anti-parasitic drug used against protozoan infections. It is widely known throughout Europe and the developing world as treatment for a variety of amoebic and parasitic infections |
Mulugetta Bezzabeh, PhD is the founder, President and CEO of Rx Africa (Ethiopia) PLC, which was founded in 2003 as Sunshine Pharmaceuticals, as a manufacturer and distributor of generic pharmaceuticals, in a joint venture with the People’s Republic of China. A factory was built and production of generic pharmaceuticals commenced. In 2006 the Chinese were bought out by private interests, with the goal of becoming one of the few FDA-GMP (Good Manufacturing Practices)-approved pharmaceutical factories in Sub-Saharan Africa.
Dr. Bezzabeh was awarded his PhD from the University of Leeds in the UK. He began his career as the Minister for Rural Development in Ethiopia. He joined the United Nations in 1980, first working from Rome, Italy at the Food and Agriculture division, and later, as the Senior Regional Advisor in the Economic Commission for Africa at the United Nations headquarters in New York City, in charge of Rural Development throughout Africa. Dr. Bezzabeh has published many articles on this subject.
On Monday April 13, 2009
NEW YORK, April 13 /PRNewswire-FirstCall/ -- A top biotech executive, William Pursley, has agreed to become Chairman of Rx for Africa, Inc.'s (Pink Sheets: RXAF - News) newly created Business Advisory Board. For 25 years Mr. Pursley has held major executive positions in the biotech industry. In 1985 he joined Genentech, Inc., and was on the marketing team that launched Human Growth Hormone (HGH), one of biotech's first products. It was a huge success. In 1985 Pursley joined Genzyme Corp as VP of Marketing and spearheaded the launch of Ceradase, an Orphan Drug for the treatment of Gaucher's Disease. Only 3,000 people in the US suffer from Gaucher's. Hopes were that the drug would reach $40 million in sales by the third year on the market. It did $120 million in year three. Ceradase has gone on to be Genzyme's biggest seller. It's sales currently exceed $600 million. Genzyme's market cap exceeds $18 billion. Mr. Pursley subsequently became CEO of Osiris Therapeutics, Inc., a leading mesenchymal stem cell company, which recently announced a major corporate alliance with Genzyme.
In 1999, Mr. Pursley joined Transkaryotic Therapeutics as Senior VP of Operations, supervising the European launch of the company's first product, Replagal, an orphan drug for Fabry's disease. The drug took 75% market share in Europe. In 2005, Transkaryotic was sold to Shire Pharmaceuticals for $1.6 billion. He has also achieved great success with reimbursement programs for the drugs he has marketed. "With Ceradase, we were successful in getting insurance companies to reimburse patients up to $350,000 a year for their treatment. Today, in Africa, there are multi-billion dollar funds such as PEPFAR and The Global Fund set up to reimburse companies who distribute drugs for disease such as HIV and malaria. I believe I can help Rx access these funds."
Pursley, who has experience marketing drugs in Africa, sees huge growth ahead for the continent. "Once the global recession lifts, I believe that Rx for Africa has the potential to dominate the sub-Saharan region of Africa, which includes Ethiopia and several neighboring countries with aggregate populations in the hundreds of millions. I believe that I can assist Rx for Africa in the launching of its HIV medications and in helping to identify a continuously updated list of the most current medication regimens to pursue as potential new products.
Mr. Pursley will also lead Rx for Africa's efforts to find US and European partners who will use Rx for Africa's low cost of manufacturing in Ethiopia to their competitive advantage. "When Rx for Africa, Inc.'s wholly-owned subsidiary's manufacturing facilities are approved by the US FDA, it should be relatively easy to find a US marketing partner in the States. Rx's cost of goods are spectacularly low and give it a competitive advantage over even India and China."
Dr. Mulugetta Bezzabeh, Chairman and CEO of Rx for Africa, Inc. commented, "We are excited about working with Mr. Pursley. His background in marketing drugs for HIV-AIDS and other diseases that have a major impact in Africa will give us tremendous insight into our task ahead."
Rx for Africa plans a conference call with investors and analysts on June 1, 2009, when Dr. Bezzabeh and Mr. Pursley will update investors on their efforts
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Rx for Africa, Inc. announced today the signing of a letter of intent for a strategic alliance with Rusan Pharma, Ltd., of Mumbai, India. The alliance commences immediately, with Rusan providing Rx for Africa Inc. the tuberculosis (TB) drug, "RUCOX-4" (four drug combination) as per the recommended dosage form of the World Health Organization (WHO), which is also approved by the Ethiopian Ministry of Health and already marketed in some CIS & African countries. Per capita the highest number of deaths and the highest mortality from TB in the world are in Sub-Saharan Africa. "Tuberculosis is a huge problem in our region," said Dr. Mulugetta Bezzabeh, CEO of Rx for Africa, "and RUCOX-4 is an important addition to our product line. We expect significant revenue and profit to be derived from marketing it."
In addition, the agreement also maps out a strategy in which Rx Africa (Ethiopia) PLC will market Rusan Pharma's 202 drugs in Ethiopia, and other sub-Saharan African countries. Importantly, Rusan will assist Rx in developing anti-malarials and HIV medications for these markets, and will assist us to start manufacturing their whole list of drugs in our Ethiopian facilities. Dr. Navin Saxena, Chairman of Rusan Pharma, Ltd. commented, "Rusan is pleased to enter into strategic alliance with Rx for Africa. Ethiopia is a big market with significant potential for growth in the area of Tuberculosis, HIV AIDS & Malaria products. Rusan has the capability to develop various drug delivery systems besides the conventional dosage forms and will use its expertise to bring these to the market in short time."
Rx for Africa's Company Website: http://www.rxforafrica.com
Rusan Pharma Ltd. of India's Company Website: http://www.rusanpharma.com/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |